moneyheap
PTCT · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is PTC Therapeutics, Inc. (PTCT) stock moving?
PTCT's fundamental news flow is strong. Q3 2026 sales of $357.8M beat the $306.4M estimate, adjusted EPS of $0.94 beat $0.34, and management raised FY2026 total revenue guidance to $1.29B-$1.32B and product revenue guidance to $960M-$990M. Sephience reached $182M in the quarter, up over 20% from Q2, with more than 2,000 active patients. Management reiterated it is on track for cash flow breakeven this year. Post-earnings, all four covering brokers that updated targets raised them: Wells Fargo to $112 (Overweight), Citigroup to $109 (Buy), TD Cowen to $95 (Buy) and RBC to $77 (Sector Perform). On Nov 3 the board authorized a $500M share repurchase, and the shares rose 6.3% to $68.12 on 2.64M shares, the heaviest volume in the period. The stock peaked at $70.11 intraday on Nov 4 and has since drifted to $64.14 on falling volume, now about 7% below that high. Recent lows near $59.2-$60 (Nov 2, Oct 30 and Oct 23) mark the nearest support, while the $68-$70 zone is the nearest resistance. Pipeline timing is a longer-term factor: the ST-920 Fabry BLA is expected to be completed in Q4 2026 with a possible 2027 launch, while the votoplam Type C meeting has slipped to Q1 2027. Overall the evidence leans positive, though the recent pullback and the mixed EPS quality (GAAP loss of $0.62) add some caution.
News behind the analysis
- PTC Therapeutics Board Authorizes $500M Share Repurchase ProgramThe Board authorized buybacks of up to $500 million of common stock, subject to market conditions, executed through open-market, privately negotiated, or accelerated repurchase methods.
- PTC Therapeutics Authorizes $500 Million Share Repurchase ProgramThe company announced a new buyback authorization of up to $500 million of outstanding common stock.
- Citigroup Maintains Buy on PTC Therapeutics, Raises Price Target to $109Citigroup reaffirmed its Buy rating and raised its price target from $108 to $109.
- PTC Therapeutics Announces Participation in Upcoming Investor ConferencesExecutives are scheduled to attend upcoming investor conferences, including the Jefferies Global Healthcare Conference.
- TD Cowen Maintains PTC Therapeutics at Buy, Raises Price Target to $95TD Cowen reaffirmed its Buy rating and raised its price target from $90 to $95.
- Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $112Wells Fargo reaffirmed its Overweight rating and raised its price target from $109 to $112.
- RBC Raises Price Target on PTC Therapeutics to $77RBC Capital Markets raised its price target from $75 to $77 and kept a Sector Perform rating.
- PTC Therapeutics Reports Third-Quarter 2026 Financial ResultsQ3 2026 total revenue was $357.8 million, including $276 million of product revenue, with a net loss of $51.7 million. Sephience generated $182 million in the quarter.
- PTC Therapeutics Raises FY2026 Sales Guidance from $1.180B-$1.280B to $1.290B-$1.320B vs $1.262B EstFull-year 2026 total revenue guidance was raised to $1.29B-$1.32B, with product revenue guidance raised to $960M-$990M, above prior expectations.
- CORRECTION: PTC Therapeutics Q3 Adj. EPS $0.94 Beats $0.34 Estimate, Sales $357.807M Beat $306.399M EstimateAdjusted EPS of $0.94 beat the $0.34 estimate and sales of $357.8M beat the $306.4M estimate. GAAP EPS was $(0.62).
About PTC Therapeutics, Inc.
PTC Therapeutics is a New Jersey-based biopharmaceutical company that discovers, develops and sells medicines for rare genetic disorders in children and adults. What sets it apart is that it earns money from several sources: its own growing drugs, especially Sephience (sepiapterin) for the metabolic disorder PKU, plus royalties and milestone payments from partners Roche and Novartis.
How it makes money
Most revenue comes from selling its own rare-disease drugs. Sephience is now the biggest of these, at about $182 million in Q3 2026, and older products such as Emflaza, Translarna and Upstaza/Kebilidi add more. Total product revenue was about $276 million in Q3 2026. A second large source is royalties on Roche's spinal muscular atrophy drug Evrysdi, worth roughly $70 million a quarter. Partner milestones add to this, such as the $50 million Novartis paid in Q2 2026 for its Huntington's disease drug votoplam. For 2026, the company guided total revenue of roughly $1.18–1.28 billion. Profits swing from quarter to quarter: it earned money in Q2 2026 and lost money in Q3 2026, partly because it bought the Fabry disease gene therapy ST-920.
What usually moves PTCT
- Sephience launch growth in the US and abroad
- Evrysdi royalties from Roche
- Votoplam Huntington's Phase 3 progress and Novartis milestones
- FDA decisions (e.g., ST-920 Fabry gene therapy, vatiquinone)
- Pipeline trial results and capital moves like buybacks or convertible notes